Drug Profile

ES 135

Alternative Names: ES-1601; ES-1602; ES-1801; ES-1901; ES-1902; ES-2301; EUSOL-rhFGF1

Latest Information Update: 13 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eusol Biotech
Class Antihyperglycaemics; Fibroblast growth factors; Peptides; Recombinant proteins; Skin disorder therapies
Mechanism of Action Fibroblast growth factor replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 May 2025 Tri-Service General Hospital completes a phase II clinical trials in Carpal tunnel syndrome in Taiwan (Intrathecal) (NCT06328166)
22 Oct 2024 Phase III development is ongoing for Spinal cord injury in Taiwan (Eusol Biotech pipeline, October 2024)
22 Oct 2024 Preclinical trials in Alopecia in Taiwan (Parenteral) prior to October 2024 (Eusol Biotech pipeline, October 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com